The body of work presented in this manuscript informed on the potential for DDIs when letermovir is administered both intravenously and orally in HSCT recipients.
No takes yet. Share an insight, caveat, or question.
Menzel et al. (2021) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: